Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, founded in 2000 and headquartered in Jerusalem, Israel. The company specializes in developing therapeutic drugs using its proprietary Accordion Pill platform technology, which was also developed in Israel. This innovative oral drug delivery system is engineered to boost the effectiveness and safety of both existing medications and those under development by employing a distinct mechanism that ensures gastric retention and a controlled release of the drug within the stomach. The company's most advanced product candidate is Accordion Pill Carbidopa/Levodopa, currently undergoing a Phase III clinical trial to manage Parkinson's disease symptoms in patients with advanced forms of the illness. Intec Pharma's pipeline also features Accordion Pill Zaleplon, which is in Phase III clinical trials as a treatment for inducing and maintaining sleep for individuals experiencing insomnia. Additionally, a product candidate designed to prevent and treat gastroduodenal and small bowel ulcers caused by Nonsteroidal Anti-Inflammatory Drugs has successfully completed its Phase I clinical trial. The company is further developing AP-CBD/THC, AP-THC, and AP-CBD, cannabinoid-based product candidates containing Cannabidiol and 9-Tetrahydrocannabinol, aimed at alleviating various pain conditions. Intec Pharma Ltd. has also entered into a research collaboration agreement with Merck to investigate the potential uses of its Accordion Pill platform in Merck's development initiatives. Originally known as Intec Pharmaceuticals (2000) Ltd., the company officially changed its name to Intec Pharma Ltd. in March 2004.